A series of layered peripheral checkpoints maintain self-reactive B cells in an unresponsive state. Autoantibody production occurs when these checkpoints are breached; however, when and how this occurs is largely unknown. In particular, how self-reactive B cells are restrained during bystander inflammation in otherwise healthy individuals is poorly understood. A weakness has been the unavailability of methods capable of dissecting physiologically relevant B cell responses without the use of an engineered BCR. Resolving this will provide insights that decipher how this process goes awry during autoimmunity or could be exploited for therapy. In this study, we use a strong adjuvant to provide bystander innate and adaptive signals that promote B cell responsiveness in conjunction with newly developed B cell detection tools to study in detail the ways that peripheral tolerance mechanisms limit the expansion and function of self-reactive B cells activated under these conditions. We show that although self-reactive B cells are recruited into the germinal center, their development does not proceed, possibly because of rapid counterselection. Consequently, differentiation of plasma cells is blunted, and Ab responses are transient and devoid of affinity maturation. We propose this approach, and these tools can be more widely applied to track Ag-specific B cell responses to more disease-relevant Ags, without the need for BCR transgenic mice, in settings where tolerance pathways are compromised or have been genetically manipulated to drive stronger insights into the biology underlying B cell-mediated autoimmunity.

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.2000377DOI Listing

Publication Analysis

Top Keywords

self-reactive cells
16
cell responses
12
peripheral tolerance
8
cell
5
cells
5
tolerance checkpoints
4
checkpoints imposed
4
imposed ubiquitous
4
ubiquitous antigen
4
antigen expression
4

Similar Publications

The carbonyl nucleobase adduct MAde is a potent antigen for adaptive polyclonal MR1-restricted T cells.

Immunity

December 2024

Experimental Immunology, Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland. Electronic address:

The major histocompatibility complex (MHC) class I-related molecule MHC-class-I-related protein 1 (MR1) presents metabolites to distinct MR1-restricted T cell subsets, including mucosal-associated invariant T (MAIT) and MR1T cells. However, self-reactive MR1T cells and the nature of recognized antigens remain underexplored. Here, we report a cell endogenous carbonyl adduct of adenine (8-(9H-purin-6-yl)-2-oxa-8-azabicyclo[3.

View Article and Find Full Text PDF

T-switch-ing TCR specificity.

Immunity

December 2024

Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine at the University of California Los Angeles (UCLA), Los Angeles, CA, USA; Department of Microbiology, Immunology, and Molecular Genetics at the University of California Los Angeles (UCLA), Los Angeles, CA, USA; Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center-UCLA, Los Angeles, CA, USA; Broad Stem Cell Research Center-UCLA, Los Angeles, CA, USA. Electronic address:

Central tolerance restricts T cells that target self-antigens. In this issue of Immunity, Abdelfattah et al. describe a method to generate self-reactive T cell receptors (TCRs) by directed evolution of non-autoreactive TCRs to recognize self-antigen peptides and demonstrate potential for T cells engineered with such receptors in immunotherapy.

View Article and Find Full Text PDF

Regulatory T cells (Tregs) actively engage in immune suppression to prevent autoimmune diseases but also inhibit anti-tumor immunity. Although Tregs express a TCR repertoire with relatively high affinities to self, they are normally quite stable and their inflammatory programs are intrinsically suppressed. We report here that diacylglycerol (DAG) kinases (DGK) ( and ( are crucial for homeostasis, suppression of proinflammatory programs, and stability of Tregs and for enforcing their dependence on CD28 costimulatory signal.

View Article and Find Full Text PDF

Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease.

J Allergy Clin Immunol

December 2024

Division of Pediatric Allergy and Immunology, Faculty of Medicine, Marmara University, Istanbul, Turkey; Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey; Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey. Electronic address:

Article Synopsis
  • STAT3 gain-of-function disease causes issues like immune system overactivity and growth problems, but long-term treatment with the JAK inhibitor ruxolitinib has shown promise in symptom relief.
  • The study monitored clinical and immune responses of four patients over a year, noting significant changes in T cell populations and the normalization of blood cell profiles, which were previously dysregulated.
  • Ruxolitinib treatment not only managed symptoms but also modified harmful immune cell characteristics and reduced certain auto-reactive T-cell clones, suggesting a potential pathway to better control the disease's impact.
View Article and Find Full Text PDF

T-Switch: A specificity-based engineering platform for developing safe and effective T cell therapeutics.

Immunity

December 2024

Department of Genetics, Harvard Medical School, Division of Genetics, Brigham and Women's Hospital, Howard Hughes Medical Institute, 77 Avenue Louis Pasteur, Boston, MA 02115, USA. Electronic address:

Many promising targets for adoptive T cell therapy (ACT) are self-antigens, but self-reactive T cells are generally eliminated during thymic selection or diverted to regulatory phenotypes. To bypass T cell tolerance and obtain potent and safe T cell therapeutics, we developed T-Switch, an in vitro T cell receptor (TCR) engineering platform for the creation, modification, and comprehensive profiling of TCRs that can target self-antigens. T-Switch first expands T cells that recognize a "foreign" peptide closely related to a self-antigen.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!